What the FDA labels say about taking them together
Ipilimumab and vemurafenib
Ipilimumab's FDA label of August 20, 2026 names vemurafenib in its warnings and precautions section, and vemurafenib's label names ipilimumab too. The vemurafenib label: “Increases in transaminases and bilirubin occurred in a majority of patients who received concurrent ipilimumab and ZELBORAF.”
Check it at the source: the ipilimumab FDA label on DailyMed (effective August 20, 2026, E.R. Squibb & Sons, L.L.C.); the vemurafenib FDA label on DailyMed (effective August 28, 2026, Genentech, Inc.).
What does the ipilimumab label say about vemurafenib?
Ipilimumab label, warnings and precautionsIn a dose-finding trial, Grade 3 increases in transaminases with or without concomitant increases in total bilirubin occurred in 6 of 10 patients who received concurrent YERVOY (3 mg/kg) and vemurafenib (960 mg or 720 mg twice daily).
Source: FDA drug label (YERVOY), E.R. Squibb & Sons, L.L.C., effective August 20, 2026 (SPL set 2265ef30-253e-11df-8a39-0800200c9a66), via openFDA; the full label on DailyMed
What does the vemurafenib label say about ipilimumab?
Vemurafenib label, drug interactionsIncreases in transaminases and bilirubin occurred in a majority of patients who received concurrent ipilimumab and ZELBORAF [see Warnings and Precautions Section 5.6 ].
Vemurafenib label, warnings and precautionsIn a dose-finding trial, Grade 3 increases in transaminases and bilirubin occurred in a majority of patients who received concurrent ipilimumab (3 mg/kg) and vemurafenib (960 mg BID or 720 mg BID) [see Drug Interactions (7.3) ].
Source: FDA drug label (ZELBORAF), NDA202429 (Hoffmann La Roche), as published by Genentech, Inc., effective August 28, 2026 (SPL set 38eea320-7e0c-485a-bc30-98c3c45e2763), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ipilimumab | Vemurafenib | |
|---|---|---|
| Labeled for | Lung cancer, Colorectal cancer | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once